{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:32:22Z","timestamp":1787563942998,"version":"build-2736575974"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03046-z","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T07:55:02Z","timestamp":1758786902000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic lymphocytic leukemia: criteria for first-line therapeutic choice\u2014an opinion paper"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8198-9812","authenticated-orcid":false,"given":"Jos\u00e9","family":"Carda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c2ngelo","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8633-6941","authenticated-orcid":false,"given":"Mar\u00edlia","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"issue":"1","key":"3046_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.019.","journal-title":"Ann Oncol"},{"issue":"9","key":"3046_CR2","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","volume":"35","author":"B Eichhorst","year":"2024","unstructured":"Eichhorst B, Ghia P, Niemann CU, Kater AP, Gregor M, Hallek M, et al. ESMO clinical practice guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia. Ann Oncol. 2024;35(9):762\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.016.","journal-title":"Ann Oncol"},{"issue":"7","key":"3046_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720\u201348. https:\/\/doi.org\/10.1038\/s41375-022-01620-2.","journal-title":"Leukemia"},{"issue":"11","key":"3046_CR4","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329(11):918\u201332. https:\/\/doi.org\/10.1001\/jama.2023.1946.","journal-title":"JAMA"},{"issue":"10","key":"3046_CR5","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1182\/blood-2009-04-214346","volume":"114","author":"P Abrisqueta","year":"2009","unstructured":"Abrisqueta P, Pereira A, Rozman C, Aymerich M, Gin\u00e9 E, Moreno C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980\u20132008): the Hospital Clinic of Barcelona experience. Blood. 2009;114(10):2044\u201350. https:\/\/doi.org\/10.1182\/blood-2009-04-214346.","journal-title":"Blood"},{"key":"3046_CR6","doi-asserted-by":"publisher","first-page":"107016","DOI":"10.1016\/j.leukres.2023.107016","volume":"125","author":"C Owen","year":"2023","unstructured":"Owen C, Banerji V, Johnson N, Gerrie A, Aw A, Chen C, et al. Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update. Leuk Res. 2023;125:107016. https:\/\/doi.org\/10.1016\/j.leukres.2023.107016.","journal-title":"Leuk Res"},{"issue":"21","key":"3046_CR7","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2019003453","volume":"135","author":"A Condoluci","year":"2020","unstructured":"Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020;135(21):1859\u201369. https:\/\/doi.org\/10.1182\/blood.2019003453.","journal-title":"Blood"},{"issue":"5","key":"3046_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/ejh.13743","volume":"108","author":"C Brieghel","year":"2022","unstructured":"Brieghel C, Galle V, Agius R, da Cunha-Bang C, Andersen MA, Vlummens P, et al. Identifying patients with chronic lymphocytic leukemia without need of treatment: end of endless watch and wait? Eur J Haematol. 2022;108(5):369\u201378. https:\/\/doi.org\/10.1111\/ejh.13743.","journal-title":"Eur J Haematol"},{"issue":"25","key":"3046_CR9","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. iwcLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360. https:\/\/doi.org\/10.1182\/blood-2017-09-806398.","journal-title":"Blood"},{"issue":"9","key":"3046_CR10","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/ajh.24826","volume":"92","author":"M Hallek","year":"2017","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92(9):946\u201365. https:\/\/doi.org\/10.1002\/ajh.24826.","journal-title":"Am J Hematol"},{"issue":"1","key":"3046_CR11","first-page":"71","volume":"3","author":"LP Kil","year":"2013","unstructured":"Kil LP, de Bruijn MJ, van Hulst JA, Langerak AW, Yuvaraj S, Hendriks RW. Bruton\u2019s tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am J Blood Res. 2013;3(1):71\u201383.","journal-title":"Am J Blood Res"},{"issue":"2","key":"3046_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40265-017-0695-3","volume":"77","author":"ED Deeks","year":"2017","unstructured":"Deeks ED. Ibrutinib: a review in chronic lymphocytic leukaemia. Drugs. 2017;77(2):225\u201336. https:\/\/doi.org\/10.1007\/s40265-017-0695-3.","journal-title":"Drugs"},{"issue":"2","key":"3046_CR13","doi-asserted-by":"publisher","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","volume":"14","author":"D Caldeira","year":"2019","unstructured":"Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS ONE. 2019;14(2):e0211228. https:\/\/doi.org\/10.1371\/journal.pone.0211228.","journal-title":"PLoS ONE"},{"key":"3046_CR14","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.2147\/dddt.S377697","volume":"16","author":"R Dong","year":"2022","unstructured":"Dong R, Yan Y, Zeng X, Lin N, Tan B. Ibrutinib-associated cardiotoxicity: from the pharmaceutical to the clinical. Drug Des Devel Ther. 2022;16:3225\u201339. https:\/\/doi.org\/10.2147\/dddt.S377697.","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"3046_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1509981.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"3046_CR16","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1182\/blood-2022-167213","volume":"140","author":"LE Roeker","year":"2022","unstructured":"Roeker LE, DerSarkissian M, Ryan KJ, Chen Y, Wahlstrom SK, Hakre S, et al. Comparing acalabrutinib and ibrutinib in the real world: a study of 2,509 patients with chronic lymphocytic leukemia. Blood. 2022;140(Supplement 1):4156\u20138. https:\/\/doi.org\/10.1182\/blood-2022-167213.","journal-title":"Blood"},{"issue":"10","key":"3046_CR17","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1080\/10428194.2021.1913144","volume":"62","author":"MS Davids","year":"2021","unstructured":"Davids MS, Telford C, Abhyankar S, Waweru C, Ringshausen I. Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-na\u00efve chronic lymphocytic leukemia. Leuk Lymphoma. 2021;62(10):2342\u201351. https:\/\/doi.org\/10.1080\/10428194.2021.1913144.","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"3046_CR18","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1182\/blood-2021-146976","volume":"138","author":"MS Davids","year":"2021","unstructured":"Davids MS, Emeribe U, Gaitonde P, Cai L. Matching-adjusted indirect treatment comparison (MAIC) of acalabrutinib alone or in combination with obinutuzumab versus ibrutinib or venetoclax plus obinutuzumab in patients with treatment-na\u00efve chronic lymphocytic leukemia. Blood. 2021;138(Supplement 1):2633\u20132633. https:\/\/doi.org\/10.1182\/blood-2021-146976.","journal-title":"Blood"},{"key":"3046_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood-2020-134280","volume":"136","author":"JR Brown","year":"2020","unstructured":"Brown JR, Robak T, Ghia P, Kahl BS, Walker P, Janowski W, et al. Efficacy and safety of Zanubrutinib in patients with treatment-na\u00efve (TN) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with del(17p): follow-up results from arm C of the SEQUOIA (BGB-3111-304) trial. Blood. 2020;136:11\u20132. https:\/\/doi.org\/10.1182\/blood-2020-134280.","journal-title":"Blood"},{"issue":"Supplement 2","key":"3046_CR20","doi-asserted-by":"publisher","first-page":"LBA-6-LBA-6","DOI":"10.1182\/blood-2022-171538","volume":"140","author":"JR Brown","year":"2022","unstructured":"Brown JR, Eichhorst B, Hillmen P, Lamanna N, O\u2019Brien SM, Tam CS, et al. Zanubrutinib demonstrates superior progression-free survival (PFS) compared with Ibrutinib for treatment of relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R\/R CLL\/SLL): results from final analysis of ALPINE randomized phase 3 study. Blood. 2022;140(Supplement 2):LBA-6-LBA-6. https:\/\/doi.org\/10.1182\/blood-2022-171538.","journal-title":"Blood"},{"issue":"26","key":"3046_CR21","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/nejm200012283432602","volume":"343","author":"H D\u00f6hner","year":"2000","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A, Leupolt E, Kr\u00f6ber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910\u20136. https:\/\/doi.org\/10.1056\/nejm200012283432602.","journal-title":"N Engl J Med"},{"issue":"4","key":"3046_CR22","doi-asserted-by":"publisher","first-page":"e707","DOI":"10.1097\/hs9.0000000000000707","volume":"6","author":"P Baliakas","year":"2022","unstructured":"Baliakas P, Espinet B, Mellink C, Jarosova M, Athanasiadou A, Ghia P, et al. Cytogenetics in chronic lymphocytic leukemia: ERIC perspectives and recommendations. Hemasphere. 2022;6(4):e707. https:\/\/doi.org\/10.1097\/hs9.0000000000000707.","journal-title":"Hemasphere"},{"issue":"28","key":"3046_CR23","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1200\/jco.2006.06.9492","volume":"24","author":"TD Shanafelt","year":"2006","unstructured":"Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006;24(28):4634\u201341. https:\/\/doi.org\/10.1200\/jco.2006.06.9492.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3046_CR24","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/s41375-022-01604-2","volume":"36","author":"A Agathangelidis","year":"2022","unstructured":"Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T, Tresoldi C, Davis Z, Giudicelli V, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European research initiative on CLL. Leukemia. 2022;36(8):1961\u20138. https:\/\/doi.org\/10.1038\/s41375-022-01604-2.","journal-title":"Leukemia"},{"issue":"7","key":"3046_CR25","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/s1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(16)30051-1.","journal-title":"Lancet Oncol"},{"issue":"Supplement_1","key":"3046_CR26","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1182\/blood-2019-122673","volume":"134","author":"E Curovic Rotbain","year":"2019","unstructured":"Curovic Rotbain E, Niemann CU, Rostgaard K, Da Cunha-Bang C, Hjalgrim H, Frederiksen H. Mapping comorbidity in CLL: impact on prognostic factors, treatment patterns and causes of death. Blood. 2019;134(Supplement_1):4285\u20134285. https:\/\/doi.org\/10.1182\/blood-2019-122673.","journal-title":"Blood"},{"issue":"3","key":"3046_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1182\/blood-2015-08-634816","volume":"127","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood. 2016;127(3):279\u201386. https:\/\/doi.org\/10.1182\/blood-2015-08-634816.","journal-title":"Blood"},{"issue":"2","key":"3046_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ctrv.2014.11.004","volume":"41","author":"P Ladyzynski","year":"2015","unstructured":"Ladyzynski P, Molik M, Foltynski P. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia. Cancer Treat Rev. 2015;41(2):77\u201393. https:\/\/doi.org\/10.1016\/j.ctrv.2014.11.004.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"3046_CR29","doi-asserted-by":"publisher","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","volume":"20","author":"WG Wierda","year":"2022","unstructured":"Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, et al. NCCN guidelines\u00ae insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 3.2022. J Natl Compr Canc Netw. 2022;20(6):622\u201334. https:\/\/doi.org\/10.6004\/jnccn.2022.0031.","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"3046_CR30","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","volume":"133","author":"P Baliakas","year":"2019","unstructured":"Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133(11):1205\u201316. https:\/\/doi.org\/10.1182\/blood-2018-09-873083.","journal-title":"Blood"},{"issue":"9836","key":"3046_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/s0140-6736(12)60240-2","volume":"380","author":"K Barnett","year":"2012","unstructured":"Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37\u201343. https:\/\/doi.org\/10.1016\/s0140-6736(12)60240-2.","journal-title":"Lancet"},{"issue":"10","key":"3046_CR32","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3324\/haematol.2014.107326","volume":"99","author":"T Baumann","year":"2014","unstructured":"Baumann T, Delgado J, Santacruz R, Mart\u00ednez-Trillos A, Royo C, Navarro A, et al. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model. Haematologica. 2014;99(10):1599\u2013604. https:\/\/doi.org\/10.3324\/haematol.2014.107326.","journal-title":"Haematologica"},{"issue":"15","key":"3046_CR33","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1002\/cncr.31554","volume":"124","author":"MJ Gordon","year":"2018","unstructured":"Gordon MJ, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock SM, et al. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 2018;124(15):3192\u2013200. https:\/\/doi.org\/10.1002\/cncr.31554.","journal-title":"Cancer"},{"issue":"6","key":"3046_CR34","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3324\/haematol.2013.096792","volume":"99","author":"V Goede","year":"2014","unstructured":"Goede V, Cramer P, Busch R, Bergmann M, Stauch M, Hopfinger G, et al. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 2014;99(6):1095\u2013100. https:\/\/doi.org\/10.3324\/haematol.2013.096792.","journal-title":"Haematologica"},{"issue":"3","key":"3046_CR35","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1080\/10428194.2016.1213831","volume":"58","author":"FJ Vojdeman","year":"2017","unstructured":"Vojdeman FJ, Van\u2019t Veer MB, Tj\u00f8nnfjord GE, It\u00e4l\u00e4-Remes M, Kimby E, Polliack A, et al. The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2017;58(3):594\u2013600. https:\/\/doi.org\/10.1080\/10428194.2016.1213831.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"3046_CR36","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41375-021-01156-x","volume":"35","author":"EC Rotbain","year":"2021","unstructured":"Rotbain EC, Niemann CU, Rostgaard K, da Cunha-Bang C, Hjalgrim H, Frederiksen H. Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death. Leukemia. 2021;35(9):2570\u201380. https:\/\/doi.org\/10.1038\/s41375-021-01156-x.","journal-title":"Leukemia"},{"issue":"21","key":"3046_CR37","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1182\/blood.V120.21.758.758","volume":"120","author":"C Reyes","year":"2012","unstructured":"Reyes C, Satram-Hoang S, Hoang K, Momin F, Guduru SR, Skettino S. What is the impact of comorbidity burden on treatment patterns and outcomes in elderly chronic lymphocytic leukemia patients? Blood. 2012;120(21):758\u2013758. https:\/\/doi.org\/10.1182\/blood.V120.21.758.758.","journal-title":"Blood"},{"issue":"3","key":"3046_CR38","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bjh.14785","volume":"178","author":"P Strati","year":"2017","unstructured":"Strati P, Parikh SA, Chaffee KG, Kay NE, Call TG, Achenbach SJ, et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol. 2017;178(3):394\u2013402. https:\/\/doi.org\/10.1111\/bjh.14785.","journal-title":"Br J Haematol"},{"key":"3046_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10215104","author":"A Fresa","year":"2021","unstructured":"Fresa A, Autore F, Galli E, Tomasso A, Stirparo L, Innocenti I, et al. Treatment options for elderly\/unfit patients with chronic lymphocytic leukemia in the era of targeted drugs: a comprehensive review. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10215104.","journal-title":"J Clin Med"},{"issue":"10","key":"3046_CR40","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/j.1532-5415.2008.01935.x","volume":"56","author":"F Salvi","year":"2008","unstructured":"Salvi F, Miller MD, Grilli A, Giorgi R, Towers AL, Morichi V, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc. 2008;56(10):1926\u201331. https:\/\/doi.org\/10.1111\/j.1532-5415.2008.01935.x.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"3046_CR41","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1532-5415.1968.tb02103.x","volume":"16","author":"BS Linn","year":"1968","unstructured":"Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16(5):622\u20136. https:\/\/doi.org\/10.1111\/j.1532-5415.1968.tb02103.x.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"3046_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341. https:\/\/doi.org\/10.1159\/000180580.","journal-title":"Nephron"},{"issue":"23","key":"3046_CR43","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1815281.","journal-title":"N Engl J Med"},{"issue":"4","key":"3046_CR44","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/bjh.16879","volume":"192","author":"MJ Gordon","year":"2021","unstructured":"Gordon MJ, Huang J, Chan RJ, Bhargava P, Danilov AV. Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials. Br J Haematol. 2021;192(4):720\u20138. https:\/\/doi.org\/10.1111\/bjh.16879.","journal-title":"Br J Haematol"},{"issue":"17","key":"3046_CR45","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1158\/1078-0432.Ccr-20-3993","volume":"27","author":"MJ Gordon","year":"2021","unstructured":"Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, et al. The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model. Clin Cancer Res. 2021;27(17):4814\u201324. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-3993.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3046_CR46","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1182\/bloodadvances.2021005716","volume":"6","author":"EC Rotbain","year":"2022","unstructured":"Rotbain EC, Gordon MJ, Vainer N, Frederiksen H, Hjalgrim H, Danilov AV, et al. The CLL comorbidity index in a population-based cohort: a tool for clinical care and research. Blood Adv. 2022;6(8):2701\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2021005716.","journal-title":"Blood Adv"},{"issue":"6","key":"3046_CR47","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"24","key":"3046_CR48","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1182\/bloodadvances.2021004824","volume":"5","author":"A Tedeschi","year":"2021","unstructured":"Tedeschi A, Frustaci AM, Mauro FR, Chiarenza A, Coscia M, Ciolli S, et al. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib? Blood Adv. 2021;5(24):5490\u2013500. https:\/\/doi.org\/10.1182\/bloodadvances.2021004824.","journal-title":"Blood Adv"},{"issue":"11","key":"3046_CR49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41408-022-00756-9","volume":"12","author":"PJ Hampel","year":"2022","unstructured":"Hampel PJ, Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 2022;12(11):161. https:\/\/doi.org\/10.1038\/s41408-022-00756-9.","journal-title":"Blood Cancer J"},{"key":"3046_CR50","unstructured":"Onkopedia. Chronic Lymphocytic Leukemia (CLL) Recommendations. 2024. https:\/\/www.onkopedia.com\/en\/onkopedia\/guidelines\/cll-2024. Accessed 18 Nov 2024"},{"key":"3046_CR51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000343608","volume":"38","author":"SG Mohile","year":"2013","unstructured":"Mohile SG, Magnuson A. Comprehensive geriatric assessment in oncology. Interdiscip Top Gerontol. 2013;38:85\u2013103. https:\/\/doi.org\/10.1159\/000343608.","journal-title":"Interdiscip Top Gerontol"},{"issue":"6","key":"3046_CR52","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3324\/haematol.2019.245803","volume":"105","author":"ERM Scheepers","year":"2020","unstructured":"Scheepers ERM, Vondeling AM, Thielen N, van der Griend R, Stauder R, Hamaker ME. Geriatric assessment in older patients with a hematologic malignancy: a systematic review. Haematologica. 2020;105(6):1484\u201393. https:\/\/doi.org\/10.3324\/haematol.2019.245803.","journal-title":"Haematologica"},{"issue":"3","key":"3046_CR53","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/10428194.2018.1508674","volume":"60","author":"S Molica","year":"2019","unstructured":"Molica S, Giannarelli D, Levato L, Mirabelli R, Levato D, Lentini M, et al. A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients. Leuk Lymphoma. 2019;60(3):845\u20137. https:\/\/doi.org\/10.1080\/10428194.2018.1508674.","journal-title":"Leuk Lymphoma"},{"key":"3046_CR54","doi-asserted-by":"publisher","first-page":"104428","DOI":"10.1016\/j.critrevonc.2024.104428","volume":"201","author":"A Stozek-Tutro","year":"2024","unstructured":"Stozek-Tutro A, Reczek M, Kawalec P. Safety profile of first-line targeted therapies in elderly and\/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2024;201:104428. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104428.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"3046_CR55","doi-asserted-by":"publisher","first-page":"101602","DOI":"10.1016\/j.jgo.2023.101602","volume":"14","author":"ED Duchesneau","year":"2023","unstructured":"Duchesneau ED, McNeill AM, Schary W, Pate V, Lund JL. Prognosis of older adults with chronic lymphocytic leukemia: a surveillance, epidemiology, and end results-medicare cohort study. J Geriatr Oncol. 2023;14(8):101602. https:\/\/doi.org\/10.1016\/j.jgo.2023.101602.","journal-title":"J Geriatr Oncol"},{"issue":"14","key":"3046_CR56","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.ejca.2008.06.018","volume":"44","author":"SO Dalton","year":"2008","unstructured":"Dalton SO, Sch\u00fcz J, Engholm G, Johansen C, Kjaer SK, Steding-Jessen M, et al. Social inequality in incidence of and survival from cancer in a population-based study in Denmark, 1994\u20132003: summary of findings. Eur J Cancer. 2008;44(14):2074\u201385. https:\/\/doi.org\/10.1016\/j.ejca.2008.06.018.","journal-title":"Eur J Cancer"},{"issue":"7","key":"3046_CR57","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/sj.bjc.6605861","volume":"103","author":"A Pokhrel","year":"2010","unstructured":"Pokhrel A, Martikainen P, Pukkala E, Rautalahti M, Sepp\u00e4 K, Hakulinen T. Education, survival and avoidable deaths in cancer patients in Finland. Br J Cancer. 2010;103(7):1109\u201314. https:\/\/doi.org\/10.1038\/sj.bjc.6605861.","journal-title":"Br J Cancer"},{"issue":"5","key":"3046_CR58","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/jech-2015-205729","volume":"70","author":"E Guillaume","year":"2016","unstructured":"Guillaume E, Pornet C, Dejardin O, Launay L, Lillini R, Vercelli M, et al. Development of a cross-cultural deprivation index in five European countries. J Epidemiol Community Health. 2016;70(5):493\u20139. https:\/\/doi.org\/10.1136\/jech-2015-205729.","journal-title":"J Epidemiol Community Health"},{"key":"3046_CR59","doi-asserted-by":"publisher","first-page":"102292","DOI":"10.1016\/j.canep.2022.102292","volume":"82","author":"B Delapierre","year":"2023","unstructured":"Delapierre B, Troussard X, Damaj G, Dejardin O, Tron L. Role of social status and social environment on net survival in patients with chronic lymphocytic leukemia: a high-resolution population-based study. Cancer Epidemiol. 2023;82:102292. https:\/\/doi.org\/10.1016\/j.canep.2022.102292.","journal-title":"Cancer Epidemiol"},{"issue":"11","key":"3046_CR60","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1182\/bloodadvances.2022008643","volume":"7","author":"AS Kittai","year":"2023","unstructured":"Kittai AS, Huang Y, Bhat SA, Paskett ED, Rogers KA, Barrientos JC, et al. Racial and socioeconomic disparities in CLL\/SLL: analysis of SEER data from 2006 to 2019. Blood Adv. 2023;7(11):2575\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2022008643.","journal-title":"Blood Adv"},{"key":"3046_CR61","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.leukres.2019.04.016","volume":"81","author":"PL Zinzani","year":"2019","unstructured":"Zinzani PL, Rambaldi A, Gaidano G, Girmenia C, Marchetti M, Pane F, et al. Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology. Leuk Res. 2019;81:88\u201394. https:\/\/doi.org\/10.1016\/j.leukres.2019.04.016.","journal-title":"Leuk Res"},{"issue":"1","key":"3046_CR62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40249-023-01056-5","volume":"12","author":"X Ye","year":"2023","unstructured":"Ye X, Wang Y, Zou Y, Tu J, Tang W, Yu R, et al. Associations of socioeconomic status with infectious diseases mediated by lifestyle, environmental pollution and chronic comorbidities: a comprehensive evaluation based on UK Biobank. Infect Dis Poverty. 2023;12(1):5. https:\/\/doi.org\/10.1186\/s40249-023-01056-5.","journal-title":"Infect Dis Poverty"},{"issue":"2","key":"3046_CR63","doi-asserted-by":"publisher","first-page":"186","DOI":"10.18553\/jmcp.2020.26.2.186","volume":"26","author":"AA Dashputre","year":"2020","unstructured":"Dashputre AA, Gatwood KS, Gatwood J. Medication adherence, health care utilization, and costs among patients initiating oral oncolytics for multiple myeloma or chronic lymphocytic leukemia\/small lymphocytic lymphoma. J Manag Care Spec Pharm. 2020;26(2):186\u201396. https:\/\/doi.org\/10.18553\/jmcp.2020.26.2.186.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"3046_CR64","doi-asserted-by":"publisher","first-page":"151338","DOI":"10.1016\/j.soncn.2022.151338","volume":"38","author":"O Cormican","year":"2022","unstructured":"Cormican O, Dowling M. Providing care to people living with a chronic hematological malignancy: a qualitative evidence synthesis of informal carers\u2019 experiences. Semin Oncol Nurs. 2022;38(6):151338. https:\/\/doi.org\/10.1016\/j.soncn.2022.151338.","journal-title":"Semin Oncol Nurs"},{"issue":"5\u20136","key":"3046_CR65","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/17512433.2024.2344665","volume":"17","author":"MD Upchurch","year":"2024","unstructured":"Upchurch MD, Muluneh B. Treatment adherence and adverse event management in chronic lymphocytic leukemia: challenges and strategies for the future. Expert Rev Clin Pharmacol. 2024;17(5\u20136):467\u201375. https:\/\/doi.org\/10.1080\/17512433.2024.2344665.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3046_CR66","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.critrevonc.2015.08.025","volume":"97","author":"AE Hall","year":"2016","unstructured":"Hall AE, Paul C, Bryant J, Lynagh MC, Rowlings P, Enjeti A, et al. To adhere or not to adhere: rates and reasons of medication adherence in hematological cancer patients. Crit Rev Oncol Hematol. 2016;97:247\u201362. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.08.025.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"3046_CR67","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12885-023-10580-4","volume":"23","author":"Y Chen","year":"2023","unstructured":"Chen Y, Chen Z, Jin H, Chen Y, Bai J, Fu G. Associations of financial toxicity with symptoms and unplanned healthcare utilization among cancer patients taking oral chemotherapy at home: a prospective observational study. BMC Cancer. 2023;23(1):140. https:\/\/doi.org\/10.1186\/s12885-023-10580-4.","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"3046_CR68","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/hon.3145","volume":"41","author":"M Hallek","year":"2023","unstructured":"Hallek M. First line therapy of CLL. Hematol Oncol. 2023;41(Suppl 1):129\u201335. https:\/\/doi.org\/10.1002\/hon.3145.","journal-title":"Hematol Oncol"},{"issue":"Supplement 1","key":"3046_CR69","doi-asserted-by":"publisher","first-page":"10803","DOI":"10.1182\/blood-2022-159648","volume":"140","author":"A Ravelo","year":"2022","unstructured":"Ravelo A, Myers K, Brumble R, Bussberg C, Koffman B, Manzoor BS, et al. Understanding patient preferences for chronic lymphocytic leukemia treatments. Blood. 2022;140(Supplement 1):10803\u20135. https:\/\/doi.org\/10.1182\/blood-2022-159648.","journal-title":"Blood"},{"key":"3046_CR70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/ppa.S289139","volume":"15","author":"H Le","year":"2021","unstructured":"Le H, Ryan K, Wahlstrom SK, Maculaitis MC, Will O, Mulvihill E, et al. Oncologist and patient preferences for novel agents in first-line treatment for chronic lymphocytic leukemia: commonalities and disconnects. Patient Prefer Adherence. 2021;15:99\u2013110. https:\/\/doi.org\/10.2147\/ppa.S289139.","journal-title":"Patient Prefer Adherence"},{"key":"3046_CR71","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.leukres.2015.11.006","volume":"40","author":"E Landfeldt","year":"2016","unstructured":"Landfeldt E, Eriksson J, Ireland S, Musingarimi P, Jackson C, Tweats E, et al. Patient, physician, and general population preferences for treatment characteristics in relapsed or refractory chronic lymphocytic leukemia: a conjoint analysis. Leuk Res. 2016;40:17\u201323. https:\/\/doi.org\/10.1016\/j.leukres.2015.11.006.","journal-title":"Leuk Res"},{"issue":"9","key":"3046_CR72","doi-asserted-by":"publisher","first-page":"e771","DOI":"10.1097\/hs9.0000000000000771","volume":"6","author":"L Laurenti","year":"2022","unstructured":"Laurenti L, Gaidano G, Mauro FR, Molica S, Pasqualetti P, Scarf\u00f2 L, et al. What are the attributes prioritized in the choice of therapy in chronic lymphocytic leukemia? A patient-physician cross-matching analysis of a discrete choice experiment. Hemasphere. 2022;6(9):e771. https:\/\/doi.org\/10.1097\/hs9.0000000000000771.","journal-title":"Hemasphere"},{"issue":"4","key":"3046_CR73","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11864-020-0715-5","volume":"21","author":"L Iovino","year":"2020","unstructured":"Iovino L, Shadman M. Novel therapies in chronic lymphocytic leukemia: a rapidly changing landscape. Curr Treat Options Oncol. 2020;21(4):24. https:\/\/doi.org\/10.1007\/s11864-020-0715-5.","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"3046_CR74","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/PPO.0000000000000411","volume":"25","author":"RA Harkins","year":"2019","unstructured":"Harkins RA, Patel SP, Flowers CR. Cost-effectiveness of new targeted agents in the treatment of chronic lymphocytic leukemia. Cancer J. 2019;25(6):418\u201327. https:\/\/doi.org\/10.1097\/PPO.0000000000000411.","journal-title":"Cancer J"},{"issue":"2","key":"3046_CR75","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","volume":"35","author":"Q Chen","year":"2017","unstructured":"Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O\u2019Brien SM, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35(2):166\u201374. https:\/\/doi.org\/10.1200\/JCO.2016.68.2856.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3046_CR76","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40273-023-01346-8","volume":"42","author":"DW Kang","year":"2024","unstructured":"Kang DW, Wang L, Short NJ, Ferrajoli A, Wang Y, Zhou S, et al. Cost effectiveness of zanubrutinib versus ibrutinib in relapsed or refractory chronic lymphocytic leukemia. Pharmacoeconomics. 2024;42(4):409\u201318. https:\/\/doi.org\/10.1007\/s40273-023-01346-8.","journal-title":"Pharmacoeconomics"},{"key":"3046_CR77","doi-asserted-by":"publisher","unstructured":"Zanubrutinib (Brukinsa): CADTH Reimbursement Recommendation, Canadian Journal of Health Technologies, September 2023, Volume 3, Issue 9. https:\/\/doi.org\/10.51731\/cjht.2023.744","DOI":"10.51731\/cjht.2023.744"},{"key":"3046_CR78","doi-asserted-by":"publisher","unstructured":"Ibrutinib (Imbruvica): CADTH Reimbursement Recommendation, Canadian Journal of Health Technologies, November 2023, Volume 3, Issue 11. https:\/\/doi.org\/10.51731\/cjht.2023.785","DOI":"10.51731\/cjht.2023.785"},{"issue":"4","key":"3046_CR79","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11899-018-0461-y","volume":"13","author":"T Hilal","year":"2018","unstructured":"Hilal T, Betcher JA, Leis JF. Economic impact of oral therapies for chronic lymphocytic leukemia-the burden of novelty. Curr Hematol Malig Rep. 2018;13(4):237\u201343. https:\/\/doi.org\/10.1007\/s11899-018-0461-y.","journal-title":"Curr Hematol Malig Rep"},{"issue":"10","key":"3046_CR80","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.clml.2023.07.011","volume":"23","author":"S Easaw","year":"2023","unstructured":"Easaw S, Ezzati S, Coombs CC. SOHO state of the art updates and next questions: updates on BTK inhibitors for the treatment of chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2023;23(10):697\u2013704. https:\/\/doi.org\/10.1016\/j.clml.2023.07.011.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"3046_CR81","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1182\/blood.2021014960","volume":"140","author":"TD Shanafelt","year":"2022","unstructured":"Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O\u2019Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140(2):112\u201320. https:\/\/doi.org\/10.1182\/blood.2021014960.","journal-title":"Blood"},{"key":"3046_CR82","doi-asserted-by":"publisher","first-page":"204062072211016","DOI":"10.1177\/20406207221101697","volume":"13","author":"JL Jensen","year":"2022","unstructured":"Jensen JL, Mato AR, Pena C, Roeker LE, Coombs CC. The potential of pirtobrutinib in multiple B-cell malignancies. Ther Adv Hematol. 2022;13:20406207221101696. https:\/\/doi.org\/10.1177\/20406207221101697.","journal-title":"Ther Adv Hematol"},{"issue":"10","key":"3046_CR83","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","volume":"133","author":"JA Burger","year":"2019","unstructured":"Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133(10):1011\u20139. https:\/\/doi.org\/10.1182\/blood-2018-10-879429.","journal-title":"Blood"},{"issue":"5","key":"3046_CR84","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874\u20139. https:\/\/doi.org\/10.3324\/haematol.2017.182907.","journal-title":"Haematologica"},{"issue":"12","key":"3046_CR85","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1097\/hs9.0000000000000801","volume":"6","author":"P Ghia","year":"2022","unstructured":"Ghia P, Pluta A, Wach M, Lysak D, \u0160imkovi\u010d M, Kriachok I, et al. Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results. Hemasphere. 2022;6(12):e801. https:\/\/doi.org\/10.1097\/hs9.0000000000000801.","journal-title":"Hemasphere"},{"issue":"31","key":"3046_CR86","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/jco.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39(31):3441\u201352. https:\/\/doi.org\/10.1200\/jco.21.01210.","journal-title":"J Clin Oncol"},{"issue":"25","key":"3046_CR87","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849\u201361. https:\/\/doi.org\/10.1200\/JCO.19.03355.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3046_CR88","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2211582.","journal-title":"N Engl J Med"},{"issue":"11","key":"3046_CR89","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1080\/03007995.2023.2262378","volume":"39","author":"CS Tam","year":"2023","unstructured":"Tam CS, Lamanna N, O\u2019Brien SM, Qiu L, Yang K, Barnes G, et al. Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE trial. Curr Med Res Opin. 2023;39(11):1497\u2013503. https:\/\/doi.org\/10.1080\/03007995.2023.2262378.","journal-title":"Curr Med Res Opin"},{"issue":"26","key":"3046_CR90","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1182\/blood.2024024667","volume":"144","author":"JR Brown","year":"2024","unstructured":"Brown JR, Eichhorst B, Lamanna N, O\u2019Brien SM, Tam CS, Qiu L, et al. Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE. Blood. 2024;144(26):2706\u201317. https:\/\/doi.org\/10.1182\/blood.2024024667.","journal-title":"Blood"},{"issue":"7","key":"3046_CR91","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO-24-02265","volume":"43","author":"M Shadman","year":"2025","unstructured":"Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, et al. Zanubrutinib versus bendamustine and rituximab in patients with treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA. J Clin Oncol. 2025;43(7):780\u20137. https:\/\/doi.org\/10.1200\/JCO-24-02265.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3046_CR92","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031\u201343. https:\/\/doi.org\/10.1016\/S1470-2045(22)00293-5.","journal-title":"Lancet Oncol"},{"issue":"4","key":"3046_CR93","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.clml.2021.09.012","volume":"22","author":"PA Thompson","year":"2022","unstructured":"Thompson PA. SOHO state of the art updates and next questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds? Clin Lymphoma Myeloma Leuk. 2022;22(4):205\u20139. https:\/\/doi.org\/10.1016\/j.clml.2021.09.012.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"3046_CR94","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","volume":"128","author":"AR Mato","year":"2016","unstructured":"Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128(18):2199\u2013205. https:\/\/doi.org\/10.1182\/blood-2016-05-716977.","journal-title":"Blood"},{"issue":"10277","key":"3046_CR95","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/s0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397(10277):892\u2013901. https:\/\/doi.org\/10.1016\/s0140-6736(21)00224-5.","journal-title":"Lancet"},{"issue":"22","key":"3046_CR96","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/JCO-25-00166","volume":"43","author":"JP Sharman","year":"2025","unstructured":"Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, et al. Phase III trial of pirtobrutinib versus idelalisib\/rituximab or bendamustine\/rituximab in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321). J Clin Oncol. 2025;43(22):2538\u201349. https:\/\/doi.org\/10.1200\/JCO-25-00166.","journal-title":"J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03046-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03046-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03046-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:34:13Z","timestamp":1762425253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03046-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":96,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["3046"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03046-z","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.C. has received travel grants from AbbVie, Janssen, Roche, Takeda, Gilead, and Beigene. In addition, J.C. has served as a consultant and\/or on the scientific advisory boards for AbbVie, Janssen, Roche, Takeda, Sanofi, BeiGene, Gilead, AstraZeneca, and Lilly. A.M. declares that there are no conflicts of interest to disclose. D.A. has served as a consultant\/advisor for AbbVie, Takeda, AstraZeneca, Roche, Lilly, Janssen-Cilag, Incyte, and Gilead. D.A. has also received lecture fees from and participated in speakers\u2019 bureaus for Janssen-Cilag, AbbVie, Takeda, AstraZeneca, Gilead, Roche, and EUSA Pharma. Additionally, D.A. is a principal investigator in clinical trials sponsored by Sanofi, Janssen-Cilag, AstraZeneca, Kartos Therapeutics, BeiGene, AbbVie, and Merck Sharp & Dohme. M.G. has received compensation for consulting services from AbbVie, AstraZeneca, Janssen-Cilag, and Takeda. As a speaker, M.G. has presented on behalf of AbbVie, Roche, Gilead, Janssen-Cilag, and Takeda. Support for participation in congresses has been provided by AbbVie, Roche, Gilead, Beigene, Janssen-Cilag, and Takeda. Additionally, M.G. has participated in expert panels for AbbVie, AstraZeneca, Lilly, Roche, Gilead, Beigene, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"493"}}